Respiratory
Respiratory diseases threaten the quality and longevity of life, and Novartis is addressing unmet needs in this area. Products include:*
- Xolair (omalizumab), a biological therapy that targets one of the underlying causes of severe allergic asthma
- TOBI (tobramycin), a nebulizer-inhaled antibiotic therapy for the treatment of Pseudomonas aeruginosa (Pa) infection in people with cystic fibrosis
- Onbrez Breezhaler (indacaterol), an inhaled once-daily bronchodilator for the treatment of chronic obstructive pulmonary disease (COPD), a group of diseases including chronic bronchitis and emphysema
In addition, Novartis has a number of compounds in late-stage development for the treatment of COPD and cystic fibrosis.
For more information, view our clinical pipeline.
*Not all indications are available in all countries.
Innovative medicines
Research
Novartis is one of the industry’s biggest investors in research.
Patient groups
Our commitment to high-quality healthcare has led to an enduring and trusted partnership between Novartis and various patient groups.
